These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

549 related articles for article (PubMed ID: 26182302)

  • 1. Comprehensive Genomic Profiling of Carcinoma of Unknown Primary Site: New Routes to Targeted Therapies.
    Ross JS; Wang K; Gay L; Otto GA; White E; Iwanik K; Palmer G; Yelensky R; Lipson DM; Chmielecki J; Erlich RL; Rankin AN; Ali SM; Elvin JA; Morosini D; Miller VA; Stephens PJ
    JAMA Oncol; 2015 Apr; 1(1):40-49. PubMed ID: 26182302
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comprehensive Genomic Profiling of Carcinoma of Unknown Primary Origin: Retrospective Molecular Classification Considering the CUPISCO Study Design.
    Ross JS; Sokol ES; Moch H; Mileshkin L; Baciarello G; Losa F; Beringer A; Thomas M; Elvin JA; Ngo N; Jin DX; Krämer A
    Oncologist; 2021 Mar; 26(3):e394-e402. PubMed ID: 33219618
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comprehensive Genomic Profiling Facilitates Implementation of the National Comprehensive Cancer Network Guidelines for Lung Cancer Biomarker Testing and Identifies Patients Who May Benefit From Enrollment in Mechanism-Driven Clinical Trials.
    Suh JH; Johnson A; Albacker L; Wang K; Chmielecki J; Frampton G; Gay L; Elvin JA; Vergilio JA; Ali S; Miller VA; Stephens PJ; Ross JS
    Oncologist; 2016 Jun; 21(6):684-91. PubMed ID: 27151654
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genomic profiling of lung adenocarcinoma patients reveals therapeutic targets and confers clinical benefit when standard molecular testing is negative.
    Lim SM; Kim EY; Kim HR; Ali SM; Greenbowe JR; Shim HS; Chang H; Lim S; Paik S; Cho BC
    Oncotarget; 2016 Apr; 7(17):24172-8. PubMed ID: 26992220
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Next-generation sequencing of adrenocortical carcinoma reveals new routes to targeted therapies.
    Ross JS; Wang K; Rand JV; Gay L; Presta MJ; Sheehan CE; Ali SM; Elvin JA; Labrecque E; Hiemstra C; Buell J; Otto GA; Yelensky R; Lipson D; Morosini D; Chmielecki J; Miller VA; Stephens PJ
    J Clin Pathol; 2014 Nov; 67(11):968-73. PubMed ID: 25078331
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genetic Profiling of Non-Small Cell Lung Cancer in Moroccan Patients by Targeted Next-Generation Sequencing.
    El Zaitouni S; Laraqui A; Ghaouti M; Benzekri A; Kettani F; Boustany Y; Benmokhtar S; Lamrani Alaoui H; El Annaz H; Abi R; Tagajdid MR; El Kochri S; El Mchichi B; Bouaiti EA; Lahlou IA; El Hassani RA; Ennibi K
    Technol Cancer Res Treat; 2024; 23():15330338241288907. PubMed ID: 39363851
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterization of Clinical Cases of Advanced Papillary Renal Cell Carcinoma via Comprehensive Genomic Profiling.
    Pal SK; Ali SM; Yakirevich E; Geynisman DM; Karam JA; Elvin JA; Frampton GM; Huang X; Lin DI; Rosenzweig M; Lipson D; Stephens PJ; Ross JS; Miller VA; Agarwal N; Shuch B; Choueiri TK; Chung JH
    Eur Urol; 2018 Jan; 73(1):71-78. PubMed ID: 28592388
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prospective comprehensive genomic profiling of advanced gastric carcinoma cases reveals frequent clinically relevant genomic alterations and new routes for targeted therapies.
    Ali SM; Sanford EM; Klempner SJ; Rubinson DA; Wang K; Palma NA; Chmielecki J; Yelensky R; Palmer GA; Morosini D; Lipson D; Catenacci DV; Braiteh F; Erlich R; Stephens PJ; Ross JS; Ou SH; Miller VA
    Oncologist; 2015 May; 20(5):499-507. PubMed ID: 25882375
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genomic Profiling of Small-Bowel Adenocarcinoma.
    Schrock AB; Devoe CE; McWilliams R; Sun J; Aparicio T; Stephens PJ; Ross JS; Wilson R; Miller VA; Ali SM; Overman MJ
    JAMA Oncol; 2017 Nov; 3(11):1546-1553. PubMed ID: 28617917
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Next-generation sequencing reveals frequent consistent genomic alterations in small cell undifferentiated lung cancer.
    Ross JS; Wang K; Elkadi OR; Tarasen A; Foulke L; Sheehan CE; Otto GA; Palmer G; Yelensky R; Lipson D; Chmielecki J; Ali SM; Elvin J; Morosini D; Miller VA; Stephens PJ
    J Clin Pathol; 2014 Sep; 67(9):772-6. PubMed ID: 24978188
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genetic characterisation of molecular targets in carcinoma of unknown primary.
    Clynick B; Dessauvagie B; Sterrett G; Harvey NT; Allcock RJN; Saunders C; Erber W; Meehan K
    J Transl Med; 2018 Jul; 16(1):185. PubMed ID: 29973234
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pulmonary Sarcomatoid Carcinomas Commonly Harbor Either Potentially Targetable Genomic Alterations or High Tumor Mutational Burden as Observed by Comprehensive Genomic Profiling.
    Schrock AB; Li SD; Frampton GM; Suh J; Braun E; Mehra R; Buck SC; Bufill JA; Peled N; Karim NA; Hsieh KC; Doria M; Knost J; Chen R; Ou SI; Ross JS; Stephens PJ; Fishkin P; Miller VA; Ali SM; Halmos B; Liu JJ
    J Thorac Oncol; 2017 Jun; 12(6):932-942. PubMed ID: 28315738
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Baseline mutational profiles of patients with carcinoma of unknown primary origin enrolled in the CUPISCO study.
    Westphalen CB; Federer-Gsponer J; Pauli C; Karapetyan AR; Chalabi N; Durán-Pacheco G; Beringer A; Bochtler T; Cook N; Höglander E; Jin DX; Losa F; Mileshkin L; Moch H; Ross JS; Sokol ES; Tothill RW; Krämer A
    ESMO Open; 2023 Dec; 8(6):102035. PubMed ID: 37922692
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comprehensive genomic profiling of relapsed and metastatic adenoid cystic carcinomas by next-generation sequencing reveals potential new routes to targeted therapies.
    Ross JS; Wang K; Rand JV; Sheehan CE; Jennings TA; Al-Rohil RN; Otto GA; Curran JC; Palmer G; Downing SR; Yelensky R; Lipson D; Balasubramanian S; Garcia L; Mahoney K; Ali SM; Miller VA; Stephens PJ
    Am J Surg Pathol; 2014 Feb; 38(2):235-8. PubMed ID: 24418857
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular driver alterations and their clinical relevance in cancer of unknown primary site.
    Löffler H; Pfarr N; Kriegsmann M; Endris V; Hielscher T; Lohneis P; Folprecht G; Stenzinger A; Dietel M; Weichert W; Krämer A
    Oncotarget; 2016 Jul; 7(28):44322-44329. PubMed ID: 27322425
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Management of advanced non-small cell lung cancers with known mutations or rearrangements: latest evidence and treatment approaches.
    Shea M; Costa DB; Rangachari D
    Ther Adv Respir Dis; 2016 Apr; 10(2):113-29. PubMed ID: 26620497
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeted Genomic Profiling Reveals Recurrent KRAS Mutations in Mesonephric-like Adenocarcinomas of the Female Genital Tract.
    Mirkovic J; McFarland M; Garcia E; Sholl LM; Lindeman N; MacConaill L; Dong F; Hirsch M; Nucci MR; Quick CM; Crum CP; McCluggage WG; Howitt BE
    Am J Surg Pathol; 2018 Feb; 42(2):227-233. PubMed ID: 28984674
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comprehensive Genomic Profiling of Advanced Esophageal Squamous Cell Carcinomas and Esophageal Adenocarcinomas Reveals Similarities and Differences.
    Wang K; Johnson A; Ali SM; Klempner SJ; Bekaii-Saab T; Vacirca JL; Khaira D; Yelensky R; Chmielecki J; Elvin JA; Lipson D; Miller VA; Stephens PJ; Ross JS
    Oncologist; 2015 Oct; 20(10):1132-9. PubMed ID: 26336083
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Integrated clinicomolecular characterization identifies RAS activation and CDKN2A deletion as independent adverse prognostic factors in cancer of unknown primary.
    Bochtler T; Reiling A; Endris V; Hielscher T; Volckmar AL; Neumann O; Kirchner M; Budczies J; Heukamp LC; Leichsenring J; Allgäuer M; Kazdal D; Löffler H; Weichert W; Schirmacher P; Stenzinger A; Krämer A
    Int J Cancer; 2020 Jun; 146(11):3053-3064. PubMed ID: 31970771
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Next-Generation Sequencing Reveals Pathway Activations and New Routes to Targeted Therapies in Cutaneous Metastatic Melanoma.
    Carlson JA; Caldeira Xavier JC; Tarasen A; Sheehan CE; Otto G; Miller VA; Stephens PJ; Elvin JA; Vergilio JA; Suh J; Gay LM; Ross JS
    Am J Dermatopathol; 2017 Jan; 39(1):1-13. PubMed ID: 28045747
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.